Clinical risk factors for endometrial hyperplastic processes in perimenopausal women


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Currently, cancers are of leading importance in the structure of mortality worldwide. Among the female population, malignant endometrial neoplasms occupy the second place in their incidence. Endometrial hyperplastic processes are presently considered to be precursors of malignant transformation, which is especially relevant in able-bodied women. There is evidence that the incidence of endometrial hyperplasia (EH) varies from 10 to 55% and reaches its maximum in the population of perimenopausal women. The paper analyzes an update on clinical risk factors for endometrial hyperplasia in perimenopausal women. Among the most significant background conditions, there are diabetes mellitus, obesity, factors of gynecological history and hormone therapy, including that for malignant breast neoplasms. Changes in the expression of estrogen and progesterone receptors play an important role in the development of pathological effects and their relationship to the development of hyperplastic processes. Conclusion. The use of molecular genetic testing in the study of the course and progression of HE and malignant transformation makes it possible to explain the mechanisms of the effects of risk factors and to clarify their significance for assessing the development of the disease. To select therapeutic tactics and to predict drug therapy success, it seems promising to evaluate the receptor status of patients with HE.

Full Text

Restricted Access

About the authors

Roya G. Huseynova

Peoples' Friendship University of Russia, Ministry of Education and Science of the Russian Federation

Email: royka.isayeva@mail.ru
postgraduate student of the Department of Obstetrics and Gynecology, Medical Institute Moscow, Russian Federation

Irina M. Ordiyants

Peoples' Friendship University of Russia, Ministry of Education and Science of the Russian Federation

Email: ordiyantc@mail.ru
Dr. Med. Sci., Professor of the Department of Obstetrics and Gynecology, Medical Institute Moscow, Russian Federation

Anastasia A. Persidskaya

Peoples' Friendship University of Russia, Ministry of Education and Science of the Russian Federation

Email: yamurzinanastya@mail.ru
postgraduate student of the Department of Obstetrics and Gynecology, Medical Institute Moscow, Russian Federation

References

  1. Петрова Г.В., Старинский В.В., Грецова О.П., Шахзадова А.О., Самсонов Ю.В. Состояние онкологической помощи населению России в 2017 г. по данным федерального статистического наблюдения. Онкология. Журнал им. П.А.Герцена. 2019; 8(1): 32-40
  2. Arem H., Irwin M.L. Obesity and endometrial cancer survival: A systematic review. Int. J. Obes. 2013; 37(5): 634-9. https://dx.doi.org/10.1038/ijo.2012.94.
  3. Cramer D.W. The epidemiology of endometrial and ovarian cancer. Hematol. Oncol. Clin. North Am. 2012; 26(1): 1-12. https://dx.doi.org/10.1016/j.hoc.2011.10.009.
  4. Burke W.M., Orr J., Leitao M., Salom E., Gehrig P., Olawaiye A.B. et al. Endometrial cancer: a review and current management strategies: Part II. Gynecol. Oncol. 2014; 134(2): 393-402. https://dx.doi.org/10.1016/j.ygyno.2014.06.003.
  5. Siegel R.L. Miller K.D., Jemal A. Cancer statistics, 2018. CA: Cancer J. Clin. 2018; 68(1): 7-30. https://dx.doi.org/10.3322/caac.21442.
  6. Аксель Е.М., Виноградова Н.Н. Статистика злокачественных новообразований женских репродуктивных органов. Онкогинекология. 2018; 27(3): 64-78.
  7. Singh G., Puckett Y. Endometrial hyperplasia. StatPearls Publishing; 2020.
  8. Jeong J.Y., Hwang S.O., Lee B., Kim K., Kim Y.B., Park S.H., Choi H.Y. Risk factors of progression to endometrial cancer in women with endometrial hyperplasia: A retrospective cohort study. PLoS One. 2020; 15(12): e0243064. https://dx.doi.org/10.1371/journal.pone.0243064.
  9. Cullen T.S. Cancer of the uterus: its pathology, symptomatology, diagnosis, and treatment. New York: D. Appleton-Century Company; 1900.
  10. Gibson D.A., Saunders P.T. Estrogen dependent signaling in reproductive tissues - A role for estrogen receptors and estrogen related receptors. Mol. Cell. Endocrinol. 2012; 348(2): 361-72. https://dx.doi.org/10.1016/j.mce.2011.09.026.
  11. Bircan S., Ensari A., Ozturk S., Erdogan N., Dundar I., Ortac F. Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium. Pathol. Oncol. Res. 2005; 11(1): 32-9.
  12. Uchikawa J., Shiozawa T., Shih H.C., Miyamoto T., Feng Y.Z., Kashima H. et al. Expression of steroid receptor coactivators and corepressors in human endometrial hyperplasia and carcinoma with relevance to steroid receptors and Ki-67 expression. Cancer. 2003; 98(10): 2207-13. https://dx.doi.org/10.1002/cncr.11760.
  13. Hu K., Zhong G., He F. Expression of estrogen receptors ERa and ERß in endometrial hyperplasia and adenocarcinoma. Int. J. Gynecol. Cancer. 2005; 15(3): 537-41. https://dx.doi.org/10.1111/j.1525-1438.2005.15321.x.
  14. Chakravarty D., Srinivasan R., Ghosh S., Rajwanshi A., Gopalan S. Estrogen receptor beta (ERß) in endometrial simple hyperplasia and endometrioid carcinoma. Appl. Immunohistochem. Mol. Morphol. 2008; 16(6): 535-42. https://dx.doi.org/10.1097/PAI.0b013e31816755a9.
  15. Пономаренко И.В., Полоников А.В., Чурносов М.И. Ассоциация полиморфизма rs4986938 гена ESR2 с развитием гиперплазии эндометрия. Акушерство и гинекология. 2019; 4: 66-72.
  16. Pieczynska B., Wojtylak S., Zawrocki A., Biernat W. Analysis of PTEN, estrogen receptor a and progesterone receptor expression in endometrial hyperplasia using tissue microarray. Pol. J. Pathol. 2011; 62(3): 133-8.
  17. Савельева Г.М., Бреусенко В.Г., Карева Е.Н., Ивановская Т.Н., Кочина Н.А., Гуторова Д.С. Изучение роли экспрессии генов рецепторов эстрогенов и прогестерона в возникновении пролиферативных процессов в эндометрии для решения вопроса о тактике ведения больных с указанными патологическими изменениями эндометрия. Российский вестник акушера-гинеколога. 2018; 18(6): 17-24.
  18. Orejuela F.J., Ramondetta L.M., Smith J., Brown J., Lemos L.B., Li Y., Hollier L.M. Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium. Gynecol. Oncol. 2005; 97(2): 483-8. https://dx.doi.org/10.1016/j.ygyno.2005.02.010.
  19. Faloppa C.C., Baiocchi G., Cunha I.W., Fregnani J.H.T.G., Osorio C.A.B.T., Fukazawa E.M. et al. NF-kB and COX-2 expression in nonmalignant endometrial lesions and cancer. Am. J. Clin. Pathol. 2014; 141(2): 196-203. https://dx.doi.org/10.1309/AJCPV7U7PGHOWEQG.
  20. Erkanli S., Bolat F., Kayaselcuk F., Demirhan B., Kuscu E. COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma. Gynecol. Oncol. 2007; 104(2): 320-5. https://dx.doi.org/10.1016/j.ygyno.2006.08.044.
  21. Ma X., Hui Y., Lin L., Wu Y., Zhang X., Liu P. Clinical significance of COX-2, GLUT-1 and VEGF expressions in endometrial cancer tissues. Pak. J. Med. Sci. 2015; 31(2): 280-4. https://dx.doi.org/10.12669/pjms.312.6604.
  22. Клинышкова Т.В., Тучанинов Д.В., Фролова Н.Б. Клинико-эпидемиологические аспекты рака тела матки с позиции профилактики рецидивирования гиперплазии эндометрия. Акушерство и гинекология. 2020; 1: 135-40
  23. Пономаренко И.В., Полоников А.В., Чурносов М.И. Гиперпластические процессы эндометрия: этиопатогенез, факторы риска, полиморфизм генов-кандидатов. Акушерство и гинекология. 2019; 1: 13-8
  24. Raglan O., Kalliala I., Markozannes G., Cividini S., Gunter M.J., Nautiyal J. et al. Risk factors for endometrial cancer: An umbrella review of the literature. Int. J. Cancer. 2019; 145(7): 1719-30. https://dx.doi.org/10.1002/ijc.31961.
  25. Wu Q.J., Li Y.Y., Tu C., Zhu J., Qian K.Q., Feng T.B. et al. Parity and endometrial cancer risk: A meta-analysis of epidemiological studies. Sci. Rep. 2015; 5: 14243. https://dx.doi.org/10.1038/srep14243.
  26. Katzenellenbogen B.S., Katzenellenbogen J.A. Estrogen receptor alpha and estrogen receptor beta: Regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res. 2000; 2(5): 335-44. https://dx.doi.org/10.1186/bcr78.
  27. Fleming C.A., Heneghan H.M., O’Brien D., McCartan D.P., McDermott E.W., Prichard R.S. Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. Br. J. Surg. 2018; 105(9): 1098-106. https://dx.doi.org/10.1002/bjs.10899.
  28. Stewart H.J., Prescott R.J., Forrest A.P. Scottish adjuvant tamoxifen trial: A randomized study updated to 15 years. J. Natl. Cancer Inst. 2001; 93(6): 456-62. https://dx.doi.org/10.1093/jnci/93.6.456.
  29. Davies C., Pan H., Godwin J., Gray R., Arriagada R., Raina V. et al. Longterm effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013; 381(9869): 805-16. https://dx.doi.org/10.1016/S0140-6736(12)61963-1.
  30. Zhang K., Luo Y., Dai H., Deng Z. Effects of bariatric surgery on cancer risk: evidence from meta-analysis. Obes. Surg. 2020; 30(4): 1265-72. https://dx.doi.org/10.1007/s11695-019-04368-4.
  31. Giannella L., Cerami L.B., Setti T., Bergamini E., Boselli F. Prediction of endometrial hyperplasia and cancer among premenopausal women with abnormal uterine bleeding. Biomed Res. Int. 2019: 8598152. https://dx.doi.org/10.1155/2019/8598152.
  32. Kacalska-Janssen O., Rajtar-Ciosek A., Zmaczynski A., Wyroba J., Milewicz T., Krzyczkowska-Sendrakowska M., Krzysiek J. Markers of insulin resistance in perimenopausal women with endometrial pathology. Ginekol. Pol. 2013; 84(11): 922-9. https://dx.doi.org/10.17772/gp/1661.
  33. Epplein M., Reed S.D., Voigt L.F., Newton K.M., Holt V.L., Weiss N.S. Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history. Am. J. Epidemiol. 2008; 168(6): 563-70. https://dx.doi.org/10.1093/aje/kwn168.
  34. Бабурин Д.В., Унанян А.Л., Сидорова И.С., Кудрина И.А., Ищенко А.И. Гиперпластические процессы эндометрия у женщин перименопаузального возраста: клинические аспекты проблемы. Архив акушерства и гинекологии им. В.Ф. Снегирева. 2017; 4(4): 201-7.
  35. Колесова Т.Е., Кбаидзе Е.Г., СтатныхН.В., Завьялова Ю.А. Значение оценки факторов риска в диагностике рака эндометрия. В кн.: Материалы XXI Международной научной конференции "Онкология - XXI век", VII Итало-Российской научной конференции по онкологии и эндокринной хирургии, XXI Международной научной конференции "Здоровье нации - XXI век". Пермь: Книжный формат; 2017: 123-7
  36. Giovannucci E., Harlan D.M., Archer M.C., Bergenstal R.M., Gapstur S.M., Habel L.A. et al. Diabetes and cancer: A consensus report. CA: Cancer J. Clin. 2010; 60(4): 207-21. https://dx.doi.org/10.3322/caac.20078.
  37. Tsilidis K.K. Type 2 diabetes and cancer: Umbrella review of meta-analyses of observationlal studies. BMJ. 2015; 350: g7607. https://dx.doi.org/10.1136/bmj.g7607.
  38. Nead K.T., Sharp S.J., Thompson D.J., Painter J.N., Savage D.B., Semple R.K. et al. Evidence of a causal association between insulinemia and endometrial cancer: a mendelian randomization analysis. J. Natl. Cancer Inst. 2015; 107(9): djv178. https://dx.doi.org/10.1093/jnci/djv178.
  39. Raffone A., Travaglino A., Saccone G., Maio A.D., Mollo A., Mascolo M. et al. Diabetes mellitus and responsiveness of endometrial hyperplasia and early endometrial cancer to conservative treatment. Gynecol. Endocrinol. 2019; 35(11): 932-7. https://dx.doi.org/10.1080/09513590.2019.1624716.
  40. Goncharenko V.M., Beniuk V.A., Kalenska O.V., Demchenko O.M., Spivak M.Y., Bubnov R.V. Predictive diagnosis of endometrial hyperplasia and personalized therapeutic strategy in women of fertile age. EPMA J. 2013; 4(1): 24. https://dx.doi.org/10.1186/1878-5085-4-24.
  41. Ponomarenko I., Reshetnikov E., Polonikov A., Sorokina I., Yermachenko A., Dvornyk V., Churnosov M. Candidate genes for age at menarche are associated with endometrial hyperplasia. Gene. 2020; 757: 144933. https://dx.doi.org/10.1016/j.gene.2020.144933.
  42. Niskakoski A., Pasanen A., Porkka N., Eldfors S., Lassus H., Renkonen-Sinisalo L. et al. Converging endometrial and ovarian tumorigenesis in Lynch syndrome: Shared origin of synchronous carcinomas. Gynecol. Oncol. 2018; 150(1): 92-8. https://dx.doi.org/10.1016/j.ygyno.2018.04.566.
  43. Киселев В.И., Сидорова И.С., Унанян А.Л., Муйжнек Е.Л. Гиперпластические процессы органов женской репродуктивной системы: теория и практика. М.: Медпрактика-М; 2011. 467c
  44. Чернуха Г.Е., Асатурова А.В., Иванов И.А., Думановская М.Р. Структура патологии эндометрия в различные возрастные периоды. Акушерство и гинекология. 2018; 8: 129-34

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies